The olfactory bulb proteotype differs across frontotemporal dementia spectrum

Attems, 2014, Olfactory bulb involvement in neurodegenerative diseases, Acta Neuropathol., 127, 459, 10.1007/s00401-014-1261-7 Doty, 2008, The olfactory vector hypothesis of neurodegenerative disease: is it viable?, Ann. Neurol., 63, 7, 10.1002/ana.21327 Rey, 2018, The olfactory bulb as the entry site for prion-like propagation in neurodegenerative diseases, Neurobiol. Dis., 109, 226, 10.1016/j.nbd.2016.12.013 Fullard, 2017, Olfactory dysfunction as an early biomarker in Parkinson's disease, Neurosci. Bull., 33, 515, 10.1007/s12264-017-0170-x Doty, 2012, Olfactory dysfunction in Parkinson disease, Nat. Rev. Neurol., 8, 329, 10.1038/nrneurol.2012.80 Doty, 2017, Olfactory dysfunction in neurodegenerative diseases: is there a common pathological substrate?, Lancet Neurol., 16, 478, 10.1016/S1474-4422(17)30123-0 Heyanka, 2014, Olfactory deficits in frontotemporal dementia as measured by the Alberta Smell Test, Appl. Neuropsychol. Adult, 21, 176, 10.1080/09084282.2013.782031 Orasji, 2016, Olfactory dysfunction in behavioral variant frontotemporal dementia, Clin. Neurol. Neurosurg., 141, 106, 10.1016/j.clineuro.2016.01.003 Silveira-Moriyama, 2010, Hyposmia in progressive supranuclear palsy, Mov. Disord., 25, 570, 10.1002/mds.22688 Li, 2016, Frontotemporal lobar degeneration: mechanisms and therapeutic strategies, Mol. Neurobiol., 53, 6091, 10.1007/s12035-015-9507-5 Mann, 2017, Frontotemporal lobar degeneration: pathogenesis, pathology and pathways to phenotype, Brain Pathol., 27, 723, 10.1111/bpa.12486 Mackenzie, 2016, Molecular neuropathology of frontotemporal dementia: insights into disease mechanisms from postmortem studies, J. Neurochem., 138, 54, 10.1111/jnc.13588 Shi, 2005, Histopathological changes underlying frontotemporal lobar degeneration with clinicopathological correlation, Acta Neuropathol., 110, 501, 10.1007/s00401-005-1079-4 Neumann, 2006, Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis, Science, 314, 130, 10.1126/science.1134108 Mackenzie, 2011, Distinct pathological subtypes of FTLD-FUS, Acta Neuropathol., 121, 207, 10.1007/s00401-010-0764-0 Luzzi, 2007, Distinct patterns of olfactory impairment in Alzheimer's disease, semantic dementia, frontotemporal dementia, and corticobasal degeneration, Neuropsychologia, 45, 1823, 10.1016/j.neuropsychologia.2006.12.008 McLaughlin, 2008, Odor identification deficits in frontotemporal dementia: a preliminary study, Arch. Clin. Neuropsychol., 23, 119, 10.1016/j.acn.2007.07.008 Pardini, 2009, Olfactory function in corticobasal syndrome and frontotemporal dementia, Arch. Neurol., 66, 92, 10.1001/archneurol.2008.521 Kovacs, 1999, beta-Amyloid deposition and neurofibrillary tangle formation in the olfactory bulb in ageing and Alzheimer's disease, Neuropathol. Appl. Neurobiol., 25, 481, 10.1046/j.1365-2990.1999.00208.x Hubbard, 2007, Alpha-synuclein pathology in the olfactory pathways of dementia patients, J. Anat., 211, 117, 10.1111/j.1469-7580.2007.00748.x Duda, 2010, Olfactory system pathology as a model of Lewy neurodegenerative disease, J. Neurol. Sci., 289, 49, 10.1016/j.jns.2009.08.042 Kohl, 2017, Distinct pattern of microgliosis in the olfactory bulb of neurodegenerative proteinopathies, Neural Plast., 2017, 10.1155/2017/3851262 Mackenzie, 2011, A harmonized classification system for FTLD-TDP pathology, Acta Neuropathol., 122, 111, 10.1007/s00401-011-0845-8 Litvan, 1996, Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders, J. Neuropathol. Exp. Neurol., 55, 97, 10.1097/00005072-199601000-00010 Dayon, 2010, Combining low- and high-energy tandem mass spectra for optimized peptide quantification with isobaric tags, J. Proteome, 73, 769, 10.1016/j.jprot.2009.10.015 Mundinano, 2011, Increased dopaminergic cells and protein aggregates in the olfactory bulb of patients with neurodegenerative disorders, Acta Neuropathol., 122, 61, 10.1007/s00401-011-0830-2 Goedert, 2015, Alzheimer's and Parkinson's diseases: the prion concept in relation to assembled Abeta, tau, and alpha-synuclein, Science, 349, 10.1126/science.1255555 Nonaka, 2013, Prion-like properties of pathological TDP-43 aggregates from diseased brains, Cell Rep., 4, 124, 10.1016/j.celrep.2013.06.007 Lachen-Montes, 2016, Deconstructing the molecular architecture of olfactory areas using proteomics, Proteom. Clin. Appl., 10, 1178, 10.1002/prca.201500147 Bronner, 2009, Comprehensive mRNA expression profiling distinguishes tauopathies and identifies shared molecular pathways, PLoS One, 4, 10.1371/journal.pone.0006826 Lachen-Montes, 2017, Olfactory bulb neuroproteomics reveals a chronological perturbation of survival routes and a disruption of prohibitin complex during Alzheimer's disease progression, Sci. Rep., 7, 9115, 10.1038/s41598-017-09481-x Lachen-Montes, 2019, Unveiling the olfactory proteostatic disarrangement in Parkinson's disease by proteome-wide profiling, Neurobiol. Aging, 73, 123, 10.1016/j.neurobiolaging.2018.09.018 Fernandez-Irigoyen, 2019, Olfactory proteotyping: towards the enlightenment of the neurodegeneration, Neural Regen. Res., 14, 979, 10.4103/1673-5374.249220 Svenningsson, 2004, DARPP-32: an integrator of neurotransmission, Annu. Rev. Pharmacol. Toxicol., 44, 269, 10.1146/annurev.pharmtox.44.101802.121415 Hemmings, 1984, DARPP-32, a dopamine-regulated neuronal phosphoprotein, is a potent inhibitor of protein phosphatase-1, Nature, 310, 503, 10.1038/310503a0 Albers, 2002, Mitochondrial dysfunction in progressive supranuclear palsy, Neurochem. Int., 40, 559, 10.1016/S0197-0186(01)00126-7 Mori, 1987, Membrane and synaptic properties of identified neurons in the olfactory bulb, Prog. Neurobiol., 29, 275, 10.1016/0301-0082(87)90024-4 Breton-Provencher, 2012, Newborn neurons in the adult olfactory bulb: unique properties for specific odor behavior, Behav. Brain Res., 227, 480, 10.1016/j.bbr.2011.08.001 Rey, 2018, Spread of aggregates after olfactory bulb injection of alpha-synuclein fibrils is associated with early neuronal loss and is reduced long term, Acta Neuropathol., 135, 65, 10.1007/s00401-017-1792-9 Tepe, 2018, Single-cell RNA-Seq of mouse olfactory bulb reveals cellular heterogeneity and activity-dependent molecular census of adult-born neurons, Cell Rep., 25, 10.1016/j.celrep.2018.11.034 Zhang, 2014, An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex, J. Neurosci., 34, 11929, 10.1523/JNEUROSCI.1860-14.2014 Kotlyar, 2014, In silico prediction of physical protein interactions and characterization of interactome orphans, Nat. Methods, 12, 79, 10.1038/nmeth.3178 Strehler, 2001, Role of alternative splicing in generating isoform diversity among plasma membrane calcium pumps, Physiol. Rev., 81, 21, 10.1152/physrev.2001.81.1.21 Brini, 2009, Plasma membrane Ca(2+)-ATPase: from a housekeeping function to a versatile signaling role, Pflugers Arch., 457, 657, 10.1007/s00424-008-0505-6 Di Leva, 2008, The plasma membrane Ca2+ ATPase of animal cells: structure, function and regulation, Arch. Biochem. Biophys., 476, 65, 10.1016/j.abb.2008.02.026 Palluzzi, 2017, A novel network analysis approach reveals DNA damage, oxidative stress and calcium/cAMP homeostasis-associated biomarkers in frontotemporal dementia, PLoS One, 12, 10.1371/journal.pone.0185797 Sochivko, 2002, The Ca(V)2.3 Ca(2+) channel subunit contributes to R-type Ca(2+) currents in murine hippocampal and neocortical neurones, J. Physiol., 542, 699, 10.1113/jphysiol.2002.020677 De Koninck, 1998, Sensitivity of CaM kinase II to the frequency of Ca2+ oscillations, Science, 279, 227, 10.1126/science.279.5348.227 Nichols, 1990, Calcium/calmodulin-dependent protein kinase II increases glutamate and noradrenaline release from synaptosomes, Nature, 343, 647, 10.1038/343647a0 Barria, 1997, Regulatory phosphorylation of AMPA-type glutamate receptors by CaM-KII during long-term potentiation, Science, 276, 2042, 10.1126/science.276.5321.2042 Lachen-Montes, 2016, An early dysregulation of FAK and MEK/ERK signaling pathways precedes the beta-amyloid deposition in the olfactory bulb of APP/PS1 mouse model of Alzheimer's disease, J. Proteome, 148, 149, 10.1016/j.jprot.2016.07.032 Ferrer, 2001, Active, phosphorylation-dependent mitogen-activated protein kinase (MAPK/ERK), stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK), and p38 kinase expression in Parkinson's disease and Dementia with Lewy bodies, J. Neural Transm. (Vienna), 108, 1383, 10.1007/s007020100015 Ferrer, 2001, Brain Pathol., 11, 144, 10.1111/j.1750-3639.2001.tb00387.x Ferrer, 2005, Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and tauopathies, Curr. Alzheimer Res., 2, 3, 10.2174/1567205052772713 Zhu, 2001, Activation and redistribution of c-jun N-terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer's disease, J. Neurochem., 76, 435, 10.1046/j.1471-4159.2001.00046.x Lagalwar, 2007, Relation of hippocampal phospho-SAPK/JNK granules in Alzheimer's disease and tauopathies to granulovacuolar degeneration bodies, Acta Neuropathol., 113, 63, 10.1007/s00401-006-0159-4 Curtis, 1999, Sending signals from the synapse to the nucleus: possible roles for CaMK, Ras/ERK, and SAPK pathways in the regulation of synaptic plasticity and neuronal growth, J. Neurosci. Res., 58, 88, 10.1002/(SICI)1097-4547(19991001)58:1<88::AID-JNR9>3.0.CO;2-R Ackermann, 2008, Phosphatidylinositide dependent kinase deficiency increases anxiety and decreases GABA and serotonin abundance in the amygdala, Cell. Physiol. Biochem., 22, 735, 10.1159/000185557 Shao, 2006, Atypical protein kinase C in neurodegenerative disease II: PKCiota/lambda in tauopathies and alpha-synucleinopathies, J. Neuropathol. Exp. Neurol., 65, 327, 10.1097/01.jnen.0000218441.00040.82 Sun, 2012, Activation of protein kinase C isozymes for the treatment of dementias, Adv. Pharmacol., 64, 273, 10.1016/B978-0-12-394816-8.00008-8 Sun, 2010, Pharmacology of protein kinase C activators: cognition-enhancing and antidementic therapeutics, Pharmacol. Ther., 127, 66, 10.1016/j.pharmthera.2010.03.001